Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib PK in Severe Renal Impairment
NCT04699877Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve extrapolated to infinity, Area under the concentration-time curve to the last measurable concentration and 5 more. Started Jan 2021; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04699877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699877.